Traded Dec 15, 2025 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Dec 15, 2025 · Filed Dec 17, 2025
The CEO of ADMA Biologics sold $119K of ADMA Biologics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$118,740
Shares × reported transaction price
40 days after results of Nov 5, 2025, 28 days before results of Jan 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +3.8% | +2.8% | +0.9% |
| 30 days | −8.1% | +3.0% | −11.1% |
| 90 days | −14.2% | −0.1% | −14.1% |
| 180 days | −54.9% | +12.4% | −67.3% |
Past results only. Not a forecast.
Traded Dec 15, 2025 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Adam S Grossman (President and CEO) sold ~$297K of ADMA Biologics, Inc.
Scheduled in advanceTraded Dec 15, 2025 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.